- Prolonged clobetasol use can cause systemic absorption leading to iatrogenic Cushing syndrome and severe glucocorticoid-induced adrenal insufficiency in adolescents.
- Clinical signs included Cushingoid facies, extensive striae, fatigue, insomnia and low mood with morning cortisol and ACTH markedly suppressed.
- Management requires stopping topical clobetasol, physiological hydrocortisone replacement, sick-day education, emergency hydrocortisone and planned adrenal function monitoring.
Cureus. 2026 Sep 29;18(9):e117155. doi: 10.7759/cureus.117155. eCollection 2026 Sep.
ABSTRACT
Potent topical corticosteroids can be absorbed systemically and cause both iatrogenic Cushing syndrome and suppression of endogenous cortisol production. Most paediatric reports involve infants, so clinically important toxicity in adolescents may be overlooked. A 15-year-old girl used clobetasol propionate 0.05% ointment for six months, with a reported cumulative exposure of 250 g and no documented interim clinical review. She developed Cushingoid facial changes, extensive lower-limb striae, fatigue, impaired concentration, insomnia, and low mood. Morning cortisol was <30 nmol/L and ACTH was <5 ng/L. An initial short Synacthen test showed cortisol concentrations of <30 nmol/L at baseline and 30 minutes and 38 nmol/L at 60 minutes, confirming severely impaired adrenal reserve. Clobetasol was discontinued. The patient was started on physiological hydrocortisone replacement, educated on sick-day rules, and supplied with emergency intramuscular hydrocortisone. Serial Synacthen testing showed partial recovery at 2.5 months and adequate adrenal reserve by seven months, allowing hydrocortisone to be discontinued. Her mood subsequently improved, while the striae faded gradually. This case demonstrates a compelling association between prolonged exposure to a very potent topical corticosteroid, clobetasol, and the development of simultaneous Cushingoid features and glucocorticoid-induced adrenal insufficiency in an adolescent. Careful diagnostic review, patient counselling, planned clinical monitoring, and recognition of adrenal suppression are important medication-safety measures when potent or very potent topical corticosteroids are prescribed.
PMID:42960230 | PMC:PMC13718705 | DOI:10.7759/cureus.117155
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

